ERIS Share Price Performance
₹1,459.70
-312.20 (-17.62%)
14.0% undervalued intrinsic discount
₹1,696.60
Fair Value
Price ₹1,459.70
AnalystConsensusTarget ₹1,696.60
Fair Value₹1,696.60
Share Pricen/a
Narrative Update • Jun 22
Eris Lifesciences Limited Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
ERIS Community Narratives
AN
Fair Value
·Fair Value ₹1.7k 14.0% undervalued intrinsic discount
India's Shift To Branded Generics Will Expand Chronic Therapy Markets
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
India's Shift To Branded Generics Will Expand Chronic Therapy Markets
Eris Lifesciences is positioned to ride India’s move toward branded medicines and the rising need for long-term treatments like diabetes and heart care, helped by new launches, deeper doctor reach, and added manufacturing capacity. The big question is whether it can execute fast enough while relying heavily on a few key products and suppliers, and while juggling tight capacity and meaningful debt.Read more
AN
₹1.7k
14.0% undervalued intrinsic discount
Fair Value
Revenue
14.56% p.a.
Profit Margin
21.87%
Future PE
32.56x
Price in 2029
₹2.42k
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
ERIS: Stable Outlook And Upcoming Board Decisions Will Drive Future Upside
Fair Value: ₹1.7k 14.0% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Eris Lifesciences Limited Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- 44.71
- 74.46%
- 19.89%
- 59.3%
About ERIS
- Founded
- 2007
- Employees
- 3354
- CEO
- WebsiteView website
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women’s health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and anti-natal care solutions. It offers its products through wholesale drug distributors, stockists, retail and e-commerce pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is headquartered in Ahmedabad, India.
Recent ERIS News & Updates
Narrative Update • Jun 05
ERIS: New Diabetes Treatment Launch Will Drive Future Upside
Analysts have trimmed their price target on Eris Lifesciences from ₹1,712.60 to ₹1,696.60 as they now apply a slightly higher discount rate, factor in more moderate revenue growth and profit margins, and assume a higher future P/E multiple. What's in the News Eris Lifesciences announced the launch of its generic semaglutide under the brand SUNDAE in India, offering multi dose vial formats at prices starting at ₹1,290 per month for 2 mg/1.5 ml and 4 mg/3 ml variants, with plans to introduce a pen device version in April priced at ₹4,000, ₹4,200 and ₹4,500 per month for the 2 mg/1.5 ml, 4 mg/3 ml and 8 mg/3 ml strengths respectively.Analysis Article • May 23
